Otsuka Seeks First Approval For Drug Tablet With Ingestible Sensor
This article was originally published in The Gray Sheet
Executive Summary
The pharma firm, looking to counter generic competition, is partnering with Proteus Digital Health on a first-of-a-kind FDA submission for a combination product of antipsychotic drug Abilify embedded with an ingestible sensor to measure adherence and physiologic response.